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We compared immunoglobulin (IgG) and acyclovir (ACV) therapies on the establishment, maintenance, and reactivation
from latency of HSV-1(McKrae) in a mouse ocular infection model. Mice were given one intraperitoneal (IP) dose of human
IgG 24 h after infection (Day 1 p.i.) or ACV in the drinking water from Days 1 to 7 p.i. Both treatments allowed similar
percentages of mice to survive the infection and decreased ocular virus shedding as compared with untreated controls. At
most time points, there were no differences between IgG- and ACV-treated animals with respect to tissue virus titers or in
the rates of virus reactivation during explant cocultivation. However, after ultraviolet exposure, HSV reactivated in 30% of
ACV-treated mice compared with 90% of IgG-treated mice (P 5 0.02). Also by quantitative PCR, we found more latent HSV-1
DNA copies in IgG-treated mice compared with those given ACV (P 5 0.02). IgG treatment protects mice from HSV-1 infection
essentially as well as ACV does. Nonetheless, it permits higher levels of latent infection and subsequent in vivo reactivation.
These studies have implications for the mechanism by which IgG functions to attenuate HSV infections and for its potential
value as a therapeutic agent in humans.
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Infection with herpes simplex virus types 1 and 2
HSV-1, HSV-2) leads to virus replication at the site of
ntry followed by centripetal transit in nerves to the
rigeminal or vertebral ganglia where the viruses estab-
ish lifelong latency (Whitley, 1996). Reactivation from
atency occurs when a stimulus triggers replication
hereby HSV travels back down the nerve to replicate at
he initial portal of entry.
Nucleoside analogues like acyclovir (ACV) that specif-
cally inhibit herpesviral DNA synthesis and viral replica-
ion (Elion et al., 1977; Schaeffer et al., 1978) proved to
ignificantly shorten and ameliorate the severity of HSV
nfections (Schaeffer et al., 1978; Corey et al., 1983;
traus et al., 1984; Boyd et al., 1988; Whitley and Gnann,
992; Rooney et al., 1993). If provided sufficiently early in
he course of infection, these drugs also may attenuate
he quantity of virus that accesses the sensory neurons
ith the result that there is a smaller reservoir of latent
irus from which subsequent reactivations could arise
Field et al., 1979). In clinical practice, however, these
nfections are not recognized in time for there to be
bvious effects on latency, as shown by a failure to alter
ubsequent rates of virus reactivation (Mertz et al., 1984).
t is this limitation that, among other factors, has led to a
1 To whom reprint requests should be addressed at 10 Center Drive,
m. 11N228, Bethesda, MD 20892-1888. Fax: (301) 496-7383. E-mail:ns44z@nih.gov.
042-6822/99
230earch for alternative or adjunctive therapeutic tools for
SV infections.
Among the ancillary strategies considered is the ad-
inistration of virus-specific immunoglobulins (IgG).
ore than two decades ago, even before the develop-
ent of potent nucleoside drugs, IgG was proven to
iminish the mortality of HSV-1-infected mice, if given
efore infection (Akerfeldt et al., 1972, 1973). These data
ere taken to indicate that antibodies could neutralize
iral infectivity in the crucial period before it binds to and
nters cells. As a virus that spreads exclusively in a
ell-to-cell fashion, however, there was reason to think
hat IgG might not ameliorate the virulence of HSV if
elivered after the onset of infection. Studies using po-
ent polyclonal and particular monoclonal antibodies
ith very high titers of virus neutralizing activity showed
hat significant benefit of IgG was afforded, even if dos-
ng was delayed for 1 to 2 days after infection (Oakes and
osemond-Hornbeak, 1978; Davis et al., 1979; McKendall
t al., 1979; Simmons and Nash, 1985). This observation
uggested that IgG conveys some activity that can block
SV spread after the onset of infection and aroused
ome enthusiasm for considering its use not only as a
rophylactic agent but as a therapeutic one as well.
With this background we sought to explore the mech-
nism of IgG action in HSV-1 infection by comparing its
herapeutic effects to those of ACV. In these studies, we
itered the virus in various neural tissues to which it
preads after infection, quantitated the number of ge-
ome copies that persisted in ganglia after infection (the
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231IgG OR ACV IN HSV PATHOGENESISatent viral load), and determined the capacity of that
irus to reactivate upon exposure to ultraviolet (UV) light.
RESULTS
urvival of animals during acute HSV-1 infection
To define the effects of ACV and IgG on virus-
nduced mortality, groups of 10 (controls) or 20 (treated)
nimals each were infected by bilateral corneal scar-
fication followed by inoculation with 1 3 106 PFU of
SV-1 (McKrae). Mortality was scored daily for the first
5 days p.i. None of the untreated animals survived
eyond Day 6 p.i., whereas all of the mock-infected
nimals survived. Oral ACV for 7 days or one dose of
gG administered 24 h after infection allowed similar
ercentages of mice to survive an otherwise lethal
noculum of HSV-1. Specifically, as shown in Fig. 1, 60%
12 of 20) of the ACV-treated mice survived compared
ith 80% (16 of 20) of the IgG-treated mice (P 5 0.21).
cular shedding during acute infection
To monitor HSV-1 shed from the site of inoculation, eye
wabs were taken on Days 2, 4, 6, 10, 12, and 14 p.i. On
ay 2 p.i., all infected animals shed virus and the percent
f animals shedding decreased over time (Fig. 2). There
ere no survivors in the untreated group after Day 5 p.i.
s expected, no virus was shed from mock-infected
nimals. A significant difference was seen only on Day
p.i. with 95% (19/20) of the IgG-treated mice shedding
irus compared with 45% (9/20) for the ACV-treated (P 5
.001). By Day 10 p.i., no virus was detected in the
FIG. 1. Survival after HSV-1 inoculation. Groups of 10 or 20 mice
ach were infected with 1 3 106 PFU of HSV-1 (McKrae) using bilateral
orneal scarification. Uninfected controls received PBS. ACV was ad-
inistered at 2mg/ml in the drinking water from 24 h (Day 1) and
ontinuing through Day 7 p.i. Animals on IgG were given a single 0.5 ml
ose IP Day 1 p.i. of pooled human IgG diluted 1:8 in PBS. Survival was
onitored for the first 15 days p.i.orneal swabs from either group. Thus the number of (nimals shedding virus was decreased over time with
oth treatments.
SV-1 titers during acute infection
To further study the effects of IgG on HSV-1 pathogen-
sis in this mouse model, we quantified the amount of
irus found in the eyes, TG and brain on Days 4, 7, 10,
nd 12 p.i. These tissues were harvested from groups of
hree mice per treatment arm at each time point. The
ock-infected animals yielded no virus on any of the
ays tested, whereas no untreated controls survived
eyond Day 8 p.i. As expected, more HSV-1 was detected
n the untreated group compared with the ACV-treated
roup (Fig. 3). The P values for differences in virus titers
etween ACV-treated and the untreated mice were: eyes
ay, 4 p.i. 5 0.05 and Day 7 , 0.001; TG Day 4 5 0.002
nd Day 7 , 0.001; brains, Day 4 5 0.001 and Day 7 5
.12. IgG treatment also decreased virus titers, particu-
arly on Day 7 p.i. The P values for differences in virus
iters between IgG-treated and the untreated mice were:
yes, Day 4 p.i. 5 0.08 and Day 7 , 0.001; TG, Day 4 5
.07 and Day7 5 0.03; brains, Day 4 5 0.33 and Day 7 5
.23. A comparison of the treatment groups showed that
irus titers from ACV- and IgG-treated mice were gener-
lly similar. On Day 4 p.i., however, IgG-treated animals
ad significantly higher levels of HSV-1 in the eyes and
G compared with animals on ACV. Specifically, the p
alues for differences between treated groups (ACV vs.
gG) were: eyes, Day 4 p.i. 5 0.04, Day 7 5 1.0, day 10 5
.37, and Day 12 5 1.0; TG, Day 4 5 0.006, Day 7 5 0.37,
ay 10 5 1.0, and Day 12 5 0.37; brains, Day 4 5 0.13,
ay 7 5 0.90, Day 10 5 1.0, and Day 12 5 1.0.
FIG. 2. Ocular shedding after HSV-1 infection. Groups of 10 or 20
ice each were infected with HSV-1 (McKrae) and treated with oral
CV or IP IgG as described in Fig. 1. On the indicated days, corneal
wabs were taken for virus isolation. Each point represents 10 micemock-infected and untreated groups) or 20 mice (treated groups).
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232 LEBLANC ET AL.xplant cocultivation of latently infected ganglia
HSV-1 establishes and maintains a latent infection in the
G and can be reactivated in vitro by explant cocultivation.
o detect any potential differences in the establishment of
atency and the rate of in vitro reactivation, HSV-1-infected
CV and IgG-treated mice were sacrificed on Day 42 p.i.,
nd their TG were harvested. Groups of 10 (mock-infected),
2 (ACV-treated), or 16 (IgG-treated) animals were studied.
xplanted ganglia were cultured for 7 days by which time
anglia from 100% of both the ACV (12/12) and IgG-treated
16/16) mice yielded CPE (Table 1). There was no significant
ifference in the average time to reactivation between the
CV and IgG groups (5.6 days vs. 5.8 days, respectively,
5 0.53). As expected, no virus reactivated from mock-
nfected TG (0/10).
n vivo reactivation of HSV-1 after UV exposure
Because mice rarely reactivate HSV spontaneously, in
ivo reactivation must be induced. Using ultraviolet radi-
FIG. 3. HSV-1 titers in the eyes, ganglia, and brain during acute infe
P IgG as described in Fig. 1. On the indicated days, the eyes, pooled T
epresents the log value of the geometric mean virus titer 6SE for thre
irus. Untreated controls did not survive beyond Day 8 p.i.
T
In Vitro and in Vivo R
Explant co-cultivation
Study group
Number of ganglion
pairs reactivating/
total tested
ock infected 0/10
CV 12/12
gG 16/16
ock infected, no UV —
CV, no UV —
gG, no UV —
a 6standard error of the mean.
b N/A; not applicable.tion as a stress (Laycock et al., 1991; LeBlanc et al.,
999), we addressed whether there would be differences
n rates of in vivo reactivation between the two treatment
roups. After latency was established (Day 71 p.i.), the
nimals were exposed to UV-B radiation for 1 min per
ye. TG were harvested 48 h later, homogenized, and
lated onto Vero cells. No virus was recovered from
V-treated, mock-infected mice. We observed significant
ifferences in the proportion of animals reactivating virus
n the ACV and IgG groups (P 5 0.02; Table 1). Consistent
ith previously published data (Blatt et al., 1993), we
ound that ACV reduced the amount of HSV reactivation
fter UV exposure of mice. Specifically, HSV-1 reacti-
ated in 30% (3/10) of ACV-treated mice compared with
0% (9/10) of IgG-treated mice. However, there was no
ifference in the average time to reactivation between
he ACV and IgG groups (15.0 vs 12.9 days, respectively;
5 0.41). To ensure that the reactivation seen was due
rimarily to the UV stress, we homogenized TG from
ice were infected with HSV-1 (McKrae) and treated with oral ACV or
brain were harvested and titers determined on Vero cells. Each point
als. Log values shown as zero actually reflect undetectable levels of
tion of Latent HSV-1
UV-irradiation
ays to
ationa
Number of ganglion
pairs reactivating/
total tested
Mean days to
CPE
Ab 0/7 N/A
1.1 3/10 15.0 6 1.8
1.2 9/10 12.9 6 1.1
0/7 N/A
2/10 17.0 6 0.0
0/10 N/Action. M
G, and
e animABLE 1
eactiva
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233IgG OR ACV IN HSV PATHOGENESISatently infected but unstressed animals: none of the
gG-treated and two of the 10 ACV-treated animals
ielded spontaneously reactivated virus.
uantitative PCR to determine latent viral load in TG
As a means of determining the amount of latent HSV-1
resent in the TG, we used a real-time QF–PCR assay
ased on displacement of a fluorescently labeled probe
o HSV-1 glycoprotein G (gG-1) sequences (LeBlanc et
l., 1999). Groups of 8 HSV-1 latently infected animals
rom each treatment arm were sacrificed on Day 44 p.i.,
nd individual ganglia were harvested for DNA extrac-
ion and subsequent PCR. By comparing the PCR results
o a standard curve run simultaneously of triplicate serial
ilutions of a gG-1 plasmid (Fig. 4), we estimated the
enome copy number in test samples. We found signif-
cantly more copies of latent HSV-1 in the IgG-treated
ice compared with those given ACV (P 5 0.02; Fig. 5).
pecifically, there was a geometric mean of 3.2 6 0.1
ogs of latent virus per 100 ng mouse TG DNA in the
CV-treated group (95% confidence interval of 3.1–3.3
ogs) vs 3.7 6 0.1 logs in the IgG-treated group (95%
onfidence interval of 3.6–3.8 logs).
DISCUSSION
During ocular HSV-1 infection, virus spreads from the
FIG. 4. The standard curve for the quantitative gG-1 DNA PCR assay.
986) were used to create a standard curve. Triplicate samples were a
enomic DNA.noculation site (eye) to the trigeminal ganglia and finally to ahe brain where it can cause encephalitis and lead to death
f the host (Whitley, 1996). The progression of disease is
ell illustrated by the data in Fig. 3. Virus initially appears in
he eye, peaks in the TG on Day 4 p.i. and later peaks in the
ns of a positive control plasmid, pSG25 (Goldin et al., 1981; Challberg,
for gG-1 DNA in the presence of 100 ng of uninfected Balb/C mouse
FIG. 5. Quantitation of latent HSV-1 DNA copy numbers by PCR.
roups of eight mice were sacrificed Day 44 p.i., and individual ganglia
ere harvested for DNA extraction. Each point represents the log value
f the geometric mean copy number for six replicate PCR determina-
ions per pooled TG from each animal. The horizontal line along the
idth of a diamond indicates the combined mean of HSV-1 DNA copy
umbers for all eight mice per group. The shorter horizontal lines aboveDilutio
mplifiednd below this indicate the 95% confidence intervals around the mean.
b
r
c
p
t
a
o
a
(
e
w
m
p
F
c
1
l
m
s
q
v
r
c
L
1
n
i
b
H
i
c
o
H
v
t
m
M
t
i
a
z
s
t
m
f
a
h
s
s
t
I
t
t
T
w
a
C
m
l
B
l
u
c
l
w
s
v
G
r
p
s
f
h
C
p
I
(
B
a
t
C
A
0
f
d
u
t
w
d
(
r
i
l
n
T
(
c
S
234 LEBLANC ET AL.rain on Day 7 p.i. Animals that survive the acute infection
etain a reservoir of latent HSV in their TG. The latent virus
an be induced to reactivate ex vivo and in vivo. The
resent studies show that IgG has significant effects on
hese various phases of HSV-1 infection even when its
dministration has been delayed until 1 day p.i.. The extent
f therapeutic benefit was generally comparable with that
fforded by acyclovir.
Animals given IgG tolerated a lethal dose of HSV-1
Fig. 1) but shed more virus and had higher titers in the
yes and TG early in infection than did animals treated
ith ACV (Figs. 2 and 3). Both the IgG- and ACV-treated
ice established latent infections as evidenced by ex-
lant, UV-irradiation, and quantitative PCR data (Table 1,
ig. 5). However, stress-induced in vivo reactivation oc-
urred in a greater percentage of IgG-treated mice (Table
), and this treatment group also had higher levels of
atent viral DNA (Fig. 5). Thus IgG, though protecting
ice from death, was less efficient at limiting the initial
pread of virus. This may, in turn, account for the subse-
uently increased latent viral load and higher rate of in
ivo reactivation compared with ACV. The higher rate of
eactivation with a higher latent viral DNA load is con-
ordant with prior reports (Maggioncalda et al., 1996;
ekstrom-Himes et al., 1998; Sawtell, 1998; Sawtell et al.,
998).
These data have implications regarding the mecha-
ism by which IgG exerts its therapeutic effects in HSV-1
nfection. The mechanism by which ACV acts seems to
e clear. Once it has been specifically phosphorylated by
SV thymidine kinase, it has affinity for and preferentially
nactivates the viral DNA polymerase compared with
ellular DNA polymerases (Elion, 1993). The mechanism
f IgG action, however, is not as obvious. As regards
SV infection, IgG has been known to neutralize cell-free
irus, to participate in antibody-dependent cellular cyto-
oxicity (ADCC), and antibody-dependent complement-
ediated cytolysis (ADCMC) (Simmons and Nash, 1985;
ester et al., 1991). Any or all of these could underlie the
herapeutic efficacy of IgG we demonstrated. Although
nfection already had occurred 1 day before the IgG was
dministered, virus that was released from dying cells in
ones of tissue necrosis could be neutralized before
preading through the bloodstream or locally to extend
he zone of infection. In future studies, we plan to give
ice either IgG or Fab fragments at various times postin-
ection to further delineate the mechanism of IgG action
s well as to address the relevance of treatment time to
uman therapy.
HSV-1 infection in mice can be fatal because of its
pread to the brain and perhaps to other vital tissues, in
harp contrast with its typical spread in immunocompe-
ent humans. This would suggest that a practical role for
gG therapy in humans, if any, might be limited to adjunc-
ive use in neonatal infection or encephalitis where ex-
ensive local and distant virus dissemination occur. these clinical applications can now be pursued in trials
ith human or humanized monoclonal antibodies (Co et
l., 1991; Sanna et al., 1996).
MATERIALS AND METHODS
ells, virus, and animals
HSV-1 strain McKrae was grown in Vero (African green
onkey kidney) cells in EMEM:199 medium (Quality Bio-
ogicals, Inc., Gaithersburg, MD) with 10% FBS (Quality
iologicals, Inc.) and 1% glutamine-streptomycin-penicil-
in (Life Technologies Gibco BRL, Gaithersburg, MD). We
sed strain McKrae because of its high neurovirulence
ompared with strains passaged multiple times in the
aboratory that typically are more attenuated. Animals
ere infected at the virus dose chosen based on pilot
tudies, which showed that to study latency and reacti-
ation, a sufficient quantity of input virus is needed.
iven the virulence of HSV-1 strain McKrae, the inoculum
equired to reproducibly yield reactivatable virus in the
resence of antiviral treatment proved 100% fatal in ab-
ence of treatment.
Female Balb/c mice, 4–6 weeks old, were obtained
rom the National Cancer Institute (Frederick, MD),
oused in American Association for Laboratory Animal
are- accredited facilities, and studied under an ap-
roved animal research protocol.
noculations and treatments
Mice were anesthetized with a 0.5 ml intraperitoneal
IP) injection of a mixture of ketamine/xylazine in PBS.
oth corneas were scarified using a 25-gauge needle
nd 5 ml of virus inoculum were applied per eye for a
otal of 1 3 106 plaque forming units (PFU) per mouse.
ontrol mice received 5 ml of PBS per scarified eye.
nimals assigned to IgG treatment were given a single
.5 ml dose IP at 24 h p.i. of pooled human IgG (prepared
or intravenous administration) (Abbott Labs, Chicago, IL)
iluted 1:8 in PBS. In our pilot studies, we found that
ndiluted IgG afforded 100% protection from death and
hat high levels of protection were maintained when IgG
as diluted 1:4 or 1:8. Thus we chose to use a 1:8
ilution, which is consistent with published reports
McKendall et al., 1979) and allowed for similar survival
ates to mice given ACV. Those on ACV (Midwest Med-
cal Supply Co., St. Louis, MO) were given the drug ad
ibitum at a dose of 2 mg/ml in the drinking water begin-
ing at 24 h (Day 1) and continuing through Day 7 p.i.
his is within the range used in prior studies (1–3 mg/ml)
Field et al., 1979; Halford et al., 1997). Water bottles were
hanged daily to ensure fresh drug preparations.
urvival and ocular virus shedding
Mice were infected using bilateral corneal scarifica-
ion and were observed daily for mortality up to Day
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235IgG OR ACV IN HSV PATHOGENESIS5 p.i. Concurrent with monitoring survival, the number of
nimals shedding virus from the cornea was determined.
n the indicated days, both eyes were swabbed with a
oistened Dacron polyester-tipped applicator (Baxter
ealthcare Corp., Deerfield, IL). The swab was placed in
ml of EMEM:199 media 1 10% FBS 1 1% glutamine-
treptomycin-penicillin 1 1.2% amphotericin B (Quality
iologicals). The culture material was plated on Vero
ells and incubated for 1 h at 37°C on a rocking platform.
fterward, cells were overlaid with media then placed in
humidified 37°C CO2 incubator until cytopathic effects
CPE) were evident.
irus titers in tissues
On Days 4, 7, 10, and 12 p.i., the eyes, brain, and
rigeminal ganglia (TG) were removed from animals us-
ng aseptic technique and placed into separate tubes
ontaining 1 ml of media (EMEM:199 1 10% FBS 1 1%
lutamine-streptomycin-penicillin 1 1.2% amphotericin
). Organs were ground using a Tekmar tissue homog-
nizer (VWR Scientific, McGaw Park, IL), and the homog-
nates were diluted serially and then plated in duplicate
n Vero cell monolayers. After a 1-h incubation at 37°C
n a rocking platform, cells were overlaid with media
ontaining 0.5% pooled human IgG (Abbott Labs) and
hen placed in a humidified 37°C CO2 incubator until
laques were evident. The dishes then were stained and
laques counted.
xplant cocultivation
Animals that survived the HSV-1 infection were al-
owed to develop latent infections by housing them for
30 days p.i. Whole trigeminal ganglia (TG) from groups
f from 10 to 16 latently infected mice were aseptically
arvested, and each pair of TG was placed onto sepa-
ate Vero cell monolayers with media containing 0.1%
,N9-hexamethylene-bis-acetamide (Sigma, St. Louis,
O) and 2% FBS. Explant cultures were kept in a 37°C
umidified CO2 incubator. The explants were checked
aily for CPE, and they were carefully transferred onto
resh monolayers weekly, if necessary.
n vivo reactivation
The protocol used for inducing HSV reactivation in vivo
as recently reported (LeBlanc et al., 1999) and is a
odification of an earlier procedure (Laycock et al.,
991). Briefly, animals were anesthetized and placed on
op of a TM-20 transilluminator (UVP Inc., Upland, CA) so
hat one side of the head was exposed at a time for 1
in. They then were turned to expose the contralateral
ye. Some infected animals were not exposed to serve
s “unstressed” controls. Forty-eight hours post-UV ex-
osure, the pair of TG from each animal was harvested,
round in 1 ml of media, and plated on Vero cells.onolayers were incubated at 37°C and checked daily
or CPE.
uantitative fluorescence (QF) PCR
The protocol used for ascertaining the latent viral ge-
ome copy number in ganglia was recently reported in
etail (LeBlanc et al., 1999). Briefly, TG pairs from latently
nfected mice were dissected, separated, and rinsed three
imes each in PBS. DNA was isolated separately from each
anglion using the Puregene DNA Isolation kit (Gentra
ystems, Minneapolis, MN). After extraction, the DNA from
oth ganglia from an animal was pooled. The number of
opies of latent HSV-1 DNA was quantified by real-time
luorescence PCR using the Taqman system, ABI Prism
700 Sequence Detector, (PE Applied Biosystems, Perkin–
lmer, Foster City, CA) with primers and probe specific for
lycoprotein G of HSV-1 (gG-1) (LeBlanc et al., 1999). Each
eaction of 100 ng TG DNA was done in triplicate, then
epeated, for a total of six runs per animal. A positive control
lasmid containing the gG-1 segment, pSG25 (Goldin et al.,
981; Challberg, 1986), was obtained from M. Challberg and
sed to develop a standard curve from 3 3 100 to 3 3 105
opies in the presence of 100 ng of uninfected Balb/c
ouse ganglia DNA.
tatistical analysis
Analyses were done using JMP software from the SAS
nstitute (Cary, NC). Comparisons between the Kaplan-
eier survival estimates were done using the log rank
est. Nonparametric methods were used to analyze other
ata. Geometric means and one-way analysis of vari-
nce with log-transformed numbers were used to ana-
yze results from acute phase tissue virus titers and
uantitative PCR. Means, medians, and distributions
ere compared by the Wilcoxon two-sample test. The
roportions of samples shedding virus, reactivating by
xplant and by UV stress were compared by two-tailed
isher exact test.
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